Pre-revenue oncology developer. Shares auditor and a scientific officer with Cascade BioSciences. Recently filed a bought-deal financing.
Veldmar says it has cash to last into Q1 2027, but doesn't show the quarterly spending assumptions or sensitivity ranges that back up the estimate.